Work Address:
`
`
`
`
`
`
`
`
`
`Home Address:
`Marital Status:
`Children:
`Birth Place:
`
`
`
`
`
`
`
`
`
`Russell J. Mumper, Ph.D.
`Curriculum Vitae
`June, 2016
`
`
`PERSONAL INFORMATION:
`
`Russell J. Mumper, Ph.D.
`Vice Provost for Academic Affairs
`
`University of Georgia
`204 Administration Building
`220 South Jackson Street
`Athens, GA 30602
`Phone: (706) 542-5806
`E-mail: mumper@uga.edu
`
`1230 Hammond Creek Trail, Watkinsville, Georgia, 30677
`Married (1990) to Natalie A. Pascuzzi (Registered Nurse)
`Ryan, Shannon, and Erin
`West Bend, Wisconsin
`
`
`PROFESSIONAL HIGHLIGHTS:
`
`
`
`
`
`
`
`Employment:
`University of Georgia (2014-present)
`University of North Carolina at Chapel Hill (2007-2014)
`University of Kentucky (1999-2007)
`ViroTex Corporation (1998-1999)
`GENEMEDICINE Inc. (1994-1998)
`Burroughs Wellcome Co. (1992-1994)
`
`Management & Leadership Experience:
`• Campuswide administration of programs and initiatives relating to faculty and academic affairs
`• University-wide oversight over SACSCOC accreditation and University SACSCOC Liaison
`• Member of SACSCOC off-site review team
`• Member of The University Cabinet, advisory to the President
`• Chair, Executive Committee, Environmental Health and Safety Management System
`• Chief Academic and Strategic Officer of a research-intensive health sciences school
`• Leadership of R&D and FDA-registered cGMP pharmaceutical manufacturing center
`• Strategic and Business Plans for academic units, centers, companies, and university
`• Co-founder of 5 start-up companies; member of BODs for angel and VC-backed companies
`• Write U.S. and foreign patent applications and respond to office actions
`• Expert patent witness including expert reports, deposition, and witness in federal trials
`• Member of federal (NIH, DOD, and NSF) Scientific Review Panels
`• Consultant to the pharmaceutical & biotechnology industries
`• Business/technology negotiations leading to contracts, licenses and MOUs
`• Creation and development of multiple Public/Private Partnerships
`
`Academic & Research Experience:
`
`• Recipient of two campuswide teaching awards at two different R1 universities
`• Educational research relating to the Flipped Classroom
`• Nanotechnology (nano-based delivery systems and nano-based sensors) and nanotoxicology
`• Cell- and tissue-specific targeting (e.g., dendritic cells, tumor cells, blood-brain barrier)
`• Vaccine delivery systems; genetic and subunit immunization; microbicide development
`• Pharmaceutical R&D and product development
`• Over $10.2M in grants/contracts as Principal Investigator (and >$28.7M total) in 15 years
`• Awarded/Completed 42 grants/contracts from Federal/Foundation sources and 41 from Industry
`• Over 300 scientific publications/abstracts and over 49 patents or patent families pending
`• Citation Report (Google Scholar): h-index: 55; i10-index: 106; Sum of Times Cited: 9588
`
`
`DRL - EXHIBIT 1047
`DRL001
`
`

`
` Russell J. Mumper, Ph.D.
`
`EDUCATION:
`
`Postdoctoral Fellowship, Protein Drug Delivery
`Center for Bioengineering, University of Washington, Seattle, Washington
`Advisor: Allan S. Hoffman, Sc.D., Professor, Bioengineering and Chemical Engineering
`
`Ph.D., Pharmaceutical Sciences (Pharmaceutics/Drug Delivery)
`College of Pharmacy, University of Kentucky, Lexington, Kentucky
`Advisor: Michael Jay, Ph.D., Professor, Pharmaceutical Sciences
`Dissertation Title: “Biodegradable Polyester Microspheres Containing Neutron Activable
`Rare-Earths for Internal Radiation Therapy.”
`
`B.A., Chemistry, with High Distinction and Departmental Honors
`University of Kentucky, Lexington, Kentucky
`
`
`
`
`1991 – 1992
`
`
`
`1991
`
`
`
`
`
`1988
`
`
`
`
`ACADEMIC PROFESSIONAL EXPERIENCE:
`
`2014 – present
`
`University of Georgia, Athens, Georgia
`
`Vice Provost for Academic Affairs (August 2014- present)
`The Vice Provost has the following responsibilities at the University of Georgia:
`
` •
`
` UGA Accreditation: University point-person for accreditation for the University of
`Georgia and Accreditation Liaison to SACSCOC
`• UGA Strategic Plan: Oversight and monitoring of progress of UGA’s 2020 Strategic
`Plan: Building on Excellence
`• UGA Program Review: Oversight over the entire Program (Academic and Support Unit)
`Review process at the University of Georgia
`• Operationalize major initiatives originating from the Provost's Office
`• Advise the Provost on several key academic appointments and appeals processes as well
`as faculty development, promotion and tenure, and related issues
`• Collaborate with Deans, Vice Presidents and Associate Provosts and units that report to
`the Provost's Office
`• Chair, UGA Arts Council
`• Chair, Executive Committee, Environmental Health and Safety Management System
`• On behalf of the President and Provost, review and render final decisions on student
`appeals in matters of academic honesty at the University of Georgia
`• Provide oversight over the following Offices/Programs:
`o Georgia Museum of Art
`o
`Institute of Higher Education
`o UGA Performing Arts Center
`o Skidaway Institute of Oceanography
`o Office of Accreditation
`o University-wide Program (Academic and Support Unit) Review
`• Serve on The University Cabinet, which functions as the University's official policy-
`making body, advisory to the President
`• Chair of other university-wide committees
`
`Highlights of major initiatives successfully led and/or completed (2014 – present):
`
`• Campuswide review and recommendations for the Environmental Safety Division,
`especially relating to UGA’s Comprehensive Environmental Health and Safety
`Management Plan (2014)
`• Campuswide revisions of all 82 promotion and tenure documents at UGA (2015)
`• Developed and implemented a centralized classroom scheduling system at UGA (2015)
`• Developed new UGA policy for faculty outside work for pay (2015)
`• Developed new UGA policy for assessment of all academic programs (2016)
`
`2
`
`
`
`
`
`
`
`
`
`
`
`
`DRL - EXHIBIT 1047
`DRL002
`
`

`
` Russell J. Mumper, Ph.D.
`
`• Validated UGA’s Signature Research Themes with Academic Analytics® (2015)
`• Expanded programming for UGA’s annual Spotlight on the Arts Festival (2014, 2015)
`
`Professor, Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy
`Professor, College of Engineering
`
`UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill,
`Chapel Hill, North Carolina
`
`
`Vice Dean (2010-2014)
`• Served as the chief academic and strategic officer of the School with wide range of
`responsibilities that spanned all missions and interfaced with all units, divisions, and
`centers/institutes
`• Supported the dean operationally within the School and the University, and substituted for the
`Dean, as required
`• Facilitated all MOUs and MOAs between School and other University units
`• Chaired the Executive Committee meetings
`• Chaired the Full Professors Committee
`• Functioned as the Equal Employment Opportunity Officer for the School
`• Functioned as the curator of key School documents including the Strategic Plan, Faculty Code
`(Governance Document), and Policies and the Procedures Governing Appointments,
`Reappointments, Promotion, and Tenure for Faculty in the School
`• Oversaw and approved External Professional Activities for Pay for Faculty in the School
`• Functioned as the Initial leader for new initiatives including InfoPorteTM and the Cooperative
`Business Cluster Model. InfoPorte is a web-based portal developed in 2007 that provides a
`consolidated view of all financial and human resource information from various University
`systems. InfoPorte is now used throughout the campus and is being integrated with
`PeopleSoft. The Cooperative Business Cluster Model was the consolidation of subject-matter
`experts in finance, human resources, IT, and pre- and post-awards into service teams that
`worked with faculty and staff to enhance operational efficiencies in an academic research
`environment.
`• Served as the liaison with the University regarding implementation of University-wide
`program activities
`• Managed areas that cut across professional education and graduate education, such as
`instructional technology, distance education, and programmatic expansion
`• Provided assistance to the division chairs with faculty recruitment processes
`• Oversaw the Appointment, Reappointment, Promotion, and Tenure process in the School
`• Provided oversight of the following Offices/Institutes/Programs:
`
` o
`
` Office of Strategic Planning and Assessment. I co-chaired the creation of the School’s
`2012-2017 Strategic Plan, which framed the School’s $100 million capital campaign.
`o The Academy at the UNC Eshelman School of Pharmacy, an Institute which includes the
`Office of Educational Technology R&D. I provided the vision for and led the
`establishment of The Academy and wrote the Instructional Innovation Policy and
`Participation Agreement which served as a vehicle for faculty to engage in highly
`innovative educational offerings that were aligned with the School’s appointment,
`promotion, and tenure policies.
`o Office of Continuing Education
`o Office of Innovative Leadership and Diversity. I led the drafting of Strategic Initiative 6
`in the Strategic Plan titled “Our People.” Two guiding principles include i) the
`recruitment of faculty and staff into career opportunities, not just jobs, and ii) the
`School’s aspiration to be a diverse community of people having the core value that a
`diversity of views, gender, races, ethnic backgrounds, and experiences of its faculty, staff
`and students is vital to allow the school to execute its mission to develop leaders who
`have a positive impact on human health worldwide.
`o Bill and Karen Campbell Faculty Mentoring Program
`
`3
`
`
`
`
`
`
`2014 – present
`
`
`2007 – 2014
`
`
`
`
`
`
`
`
`
`DRL - EXHIBIT 1047
`DRL003
`
`

`
` Russell J. Mumper, Ph.D.
`
`John A. McNeill Distinguished Professor, Division of Molecular Pharmaceutics (2007-2014)
`Research programs were focused primarily in five areas including; 1) nanotemplate
`engineering of nano-based detection devices and cell-specific nanoparticles for tumor and
`dendritic cell targeting and vaccines, 2) biocompatibility, hemocompatibility, and toxicology
`of nanoparticles and nanomaterials, 3) antibody-drug conjugates, 4) mucoadhesive gels, thin-
`films, and intravaginal rings for (trans)mucosal delivery of drugs, vaccines, and microbicides,
`and 5) anticancer and anti-inflammatory properties of berries and berry extracts. NIH, NSF,
`and industrial funding for these programs as well as others are listed under “Research Grants
`Awarded.”
`
`Professor, UNC/NCSU Joint Department of Biomedical Engineering at UNC-Chapel Hill
`(2010-2014)
`Co-Director, UNC Institute for Nanomedicine (2008-2012)
`Full Member, UNC Lineberger Comprehensive Cancer Center (2007-2014)
`Founding Director, Center for Nanotechnology in Drug Delivery (2007-2012)
`
`College of Pharmacy, University of Kentucky, Lexington, Kentucky
`
`Vice Chair, Department of Pharmaceutical Sciences (2004-2007)
`Associate Professor, Pharmaceutical Sciences (2004-2007): early tenure Jan. 1, 2004
`
`Associate Director, Center for Pharmaceutical Science and Technology (2003-2006)
`
`The Center for Pharmaceutical Science and Technology (CPST) was the College of
`Pharmacy’s analytical and formulation development and FDA-registered cGMP clinical trial
`manufacturing facility. As Associate Director, I oversaw selected operations of the Center
`pertaining to Business Development, Formulation Development, consulting, writing grant
`proposals, and negotiating contracts. As Principal Investigator on many projects, I worked
`closely with clients, the Director of the CPST and the Managing Director in overseeing all
`aspects of selected projects to their successful completion. From 1999 to 2006, working with
`seven different clients, I led the CPST’s efforts to complete seven full product development
`(analytical, formulation, manufacturing, quality control) leading to the successful submission
`of INDs and commencement of human clinical trials. The CPST became a for-profit
`company, Coldstream Laboratories Inc., in 2007.
`
`Assistant Professor, Pharmaceutical Sciences (1999-2003)
`Assistant Director, Center for Pharmaceutical Science and Technology (1999-2003)
`
`INDUSTRIAL PROFESSIONAL EXPERIENCE:
`
`ViroTex Corporation, The Woodlands, Texas
`
`
`
`Director of Product Development: Designed, optimized, and scaled-up drug delivery systems
`for skin and mucosal delivery. Developed and validated analytical assays for the development
`of these delivery systems as products. Delivery systems were primarily polymer-based
`formulations applied as films, gels, pump sprays, or aerosols. Led research effort on the
`application of ViroTex’s BEMATM (BioErodible MucoAdhesive) delivery technology for
`mucosal vaccines based on protein antigens with or without adjuvants. Established and
`managed two academic collaborations investigating novel mucosal vaccine candidates.
`Note: ViroTex was sold to Atrix Laboratories, Inc. in Nov. 1998; Atrix was subsequently
`sold to QLT, Inc. of Canada in 2005.
`
`GENEMEDICINE Inc., The Woodlands, Texas
`(GENEMEDICINE merged with Megabios and became Valentis, Inc. in 1999)
`
`Project Team Leader, Infectious Disease Product Discovery (1997-1998): Led a team of
`scientists involved with the discovery and application of novel genetic vaccines for infectious
`diseases caused by bacterial and viral pathogens. The lead product target was Helicobacter
`
`4
`
`
`
`
`
`
`
`
`
`
`
`
`
`1999 – 2007
`
`
`
`
`
`
`
`
`
`
`
`
`
`1998 – 1999
`
`
`
`1994 – 1998
`
`
`
`
`
`
`DRL - EXHIBIT 1047
`DRL004
`
`

`
` Russell J. Mumper, Ph.D.
`
`pylori. The team also assessed the efficacy of proprietary formulations administered with
`needle-free injection devices to dogs. Responsible for long term technical planning of the
`projects and for leading discussions with potential corporate partners. Managed two external
`collaborations with Baylor College of Medicine and MD Anderson Cancer Center.
`
`Project Team Leader, Antigen Presenting Cell (APC) Targeting (1996-1997): Coordinated
`and directed a team of twelve scientists that worked to target genetic vaccines to immature
`dendritic cells residing in the skin epidermis (Langerhans cells) and mature dendritic cells in
`the draining lymph nodes. Managed annual research/personnel budget of $1.75 million.
`
`Group Leader, Polymer Systems Group, Gene Delivery Sciences (1995-1996): Group Leader
`of five scientists that worked on the discovery of polymeric gene delivery systems including
`protective, interactive, non-condensing (PINCTM) polymers and chitosan-based systems.
`Coordinated and implemented the synthetic, analytical, and formulation efforts across a
`matrix of Program Teams (Cancer, Vaccines, Muscle/Growth Factors). Member of the
`Institutional Animal Care and Use Committee (IACUC).
`
`Senior Scientist, Gene Delivery Department (1994-1995): Led a team of four formulation
`scientists pursuing the research, development, and scale-up of delivery systems for plasmid
`DNA. The delivery systems included cell-targeted plasmid complexes, dry powders,
`protective interactive non-condensing (PINCTM) systems, and novel condensing agents such
`as dendrimers and chitosan analogues. Managed collaborations with two academic groups.
`Led the discovery, development, and scale-up of a stable, one-vial, lyophilized formulation
`for human Insulin-like Growth Factor (hIGF-I) Gene Medicine for potential treatment of
`neuromuscular diseases.
`
`Burroughs Wellcome Co., Pharmaceutical Research and Development
`Laboratories, Greenville, North Carolina (now GlaxoSmithKline)
`
`Development Scientist III, Solid Formulation Development, New Products: Designed,
`manufactured, and optimized oral dosage forms for new chemical entities. Wrote CMC
`sections for two INDs, sections of one NDA (VALTREX®), and several other regulatory
`documents. Research focused on solids characterization, solid state stability, and novel drug
`delivery systems.
`
`FOUNDED START-UP COMPANIES and ENTREPRENERIAL INITITIVES:
`
`Capture Pharmaceuticals, Inc. Chapel Hill, North Carolina
`
`Co-Founder: Co-founded Capture Pharmaceuticals, Inc. to develop and commercialize orally
`and topically bioavailable metal chelators for radionuclide decorporation and to ameliorate
`toxicity due to MRI contrast agents. Co-inventor on intellectual property developed at the
`University of Kentucky and University of North Carolina through a series of contracts and
`grants (~$12.5 million total) from the Department of Homeland Security, NIH-NIAID and
`NIH-NCI (project number 1R41CA203571-01).
`
`Four Tigers, LLC, and Berryceuticals, LLC, Lexington and Paris, Kentucky
`
`Co-Founder and Chief Scientific Officer: Co-founded Four Tigers, LLC in 2004 and
`Berryceuticals, LLC in 2007 to develop and commercialize various medical and health
`products derived from blackberries, the State fruit of Kentucky. Four Tigers’ lead products,
`, were launched in June
`BerryCare Toothpaste GumTM and BerryCare Quick Energy GumTM
`2013. In July 2013, Four Tigers’ first corporate IND for FT1701 was filed and received the go
`ahead from the FDA. FT1701 is a blackberry chewing gum being developed as a potential
`botanical drug product for the treatment and prevention of gingivitis. A phase I/II clinical
`trial at the University of Kentucky began in June 2014 and was funded via an awarded phase
`II STTR grant (R42DE018839) from NIH-NIDCR with matched funding from the State of
`Kentucky’s competitive SBIR-STTR Matching Funds Program.
`
`
`
`
`
`
`1992 – 1994
`
`
`
`
`
`
`2009 – present
`
`
`
`
`2004 – 2015
`
`
`
`
`
`5
`
`
`
`DRL - EXHIBIT 1047
`DRL005
`
`

`
` Russell J. Mumper, Ph.D.
`
`Ionx Capital Holdings, Inc. Lexington, Kentucky
`
`Member, Board of Directors and Executive Committee: Ionx Capital Holdings, Inc. is a
`science-driven investment and development company in the human and animal health and
`consumer product industries. Ionx first product is IonXTM Body Temperature Alert Patch to
`prevent heat-related deaths. Rights to this product and associated intellectual properties were
`sold to Hot Dot Inc. on September 27, 2011. Ionx is now developing a wristband to be worn
`to prevent heat-related deaths.
`
`NanoMed Pharmaceuticals Inc., Kalamazoo, Michigan
`
`Co-Founder: Co-founded NanoMed and was the co-inventor on all founding technology.
`NanoMed is developing nanoparticle-based advanced drug delivery systems to diagnose and
`treat disease. Negotiated two worldwide exclusive licenses from the University of Kentucky
`Research Foundation. Wrote initial business plan and all US and foreign patent applications.
`Successfully recruited President & CEO and helped to raise Series ‘A’ and ‘A2’ funds.
`Served on the Board of Directors until 2009.
`
`
`
`
`2009 – 2014
`
`
`
`
`2000 – 2009
`
`
`
`
`
`
`
`PROFESSIONAL AFFILIATIONS:
`
`International Center for Academic Integrity (2014- present)
`Phi Lambda Sigma Pharmacy Leadership Society (2013-2014)
`Rho Chi Pharmaceutical Society (1988-2014)
`American Association of Pharmaceutical Scientists (AAPS) (1988-2014)
`Controlled Release Society (CRS) (1990-2003)
`American Society of Gene Therapy (ASGT) (1997-2002)
`Sigma Xi Scientific Research Society (1987-2002)
`
`American Association of Colleges of Pharmacy (AACP) (1999-2001)
`
`
`HONORS, AWARDS, and OTHER ACTIVITIES:
`
`
`2009–2015 Steering Committee Member, AAPS Nanotechnology Focus Group
`Molecules Best Paper Award 2014. “Best Paper” award recognizes the most outstanding papers
`2014
`
`in the area of natural products, medicinal chemistry and molecular diversity. Received 2nd Prize for
`review by J Dai and RJ Mumper titled “Plant Phenolics: Extraction, Analysis and Their Antioxidant
`and Anticancer Properties” published in Molecules, 2010, 15(10), 7313–7352. The paper is currently
`the most highly cited paper in the journal’s history.
`2013–2014 Academic Faculty Advisor, Sigma Phi Epsilon Fraternity, UNC Chapel Hill
`2013
`2013 University of Kentucky Outstanding Graduate Program Alumnus for the Pharmaceutical
`Sciences
`Keynote Speaker - 2013 Commencement, UNC Eshelman School of Pharmacy
`PY1 Instructor of the Year, UNC Eshelman School of Pharmacy
`2013 Distinguished Teaching Award for Post-Baccalaureate Instruction. This is a campuswide award
`at UNC-Chapel Hill to recognize the important role of post-baccalaureate teaching.
`Elected Member, Epsilon Chapter of the Phi Lambda Sigma Pharmacy Leadership Society
`Harvard Macy Scholar, Harvard Macy Institute’s 2012 Program for Leading Innovations in Healthcare
`and Education
`Acceptance of project titled “Oil-filled Nanocapsules Containing a Docetaxel Lipid-Conjugate for
`Treatment of Non-Small Cell Lung Cancer” into the Nanotechnology Characterization Lab’s
`Advanced Technology Program at the National Cancer Institute. This was the first nanotechnology-
`based cancer technology/product developed at UNC to be accepted into the Program
`PY1 Instructor of the Year, UNC Eshelman School of Pharmacy
`Advisory Scientific Panel. The Fourth International Conference on Modern Vaccines Adjuvants &
`Delivery Systems. Copenhagen, Denmark. July 4-6, 2012
`2010–2012 Chair, Bio-Targeting Working Group, NCI Alliance for Nanotechnology in Cancer
`2009
`Elected Fellow, American Association of Pharmaceutical Scientists (AAPS)
`
`2013
`2013
`2013
`
`2013
`2012
`
`2012
`
`2012
`2012
`
`
`
`
`6
`
`
`
`DRL - EXHIBIT 1047
`DRL006
`
`

`
`
`
` Russell J. Mumper, Ph.D.
`
`2009
`
`2009
`
`2009
`
`2008
`
`2007
`
`2007
`
`2007
`
`2006
`2006
`
`External Reviewer. The University of Texas at Austin College of Pharmacy Research and Graduate
`Program. June 9-12, 2009
`Advisory Scientific Panel. The Third International Conference on Modern Vaccines Adjuvants &
`Delivery Systems. The Austrian Industrial Association, Vienna, Austria. October 28-30, 2009
`Lead Organizer. Fourth Annual Chapel Hill Drug Conference. “The Use of Nanotechnology to Create
`Safe and Effective Therapeutic and Diagnostic Products.” University of North Carolina at Chapel Hill.
`May 13-14, 2009. PI on proposal to fund conference via several corporate sponsors as well as the
`North Carolina Biotechnology Center
`Co-coordinator of “Nanotechnology Congress on Pharmaceutical Applications.” Instituto de
`Ingenieros Químicos, Colegio de Ingenieros y Agrimensores de Puerto Rico. San Juan, Puerto Rico.
`March 7, 2008
`Peer-reviewed papers published in Eur. J. Pharm. Biopharm (2005) and J. Con. Rel. (2004) listed as
`top-ten most cited papers in the journals for these years
`2007 Great Teacher Award. The UK Alumni Association Great Teacher Award recognizes annually
`six outstanding faculty members at UK for their work in the classroom. It is the oldest, continuously
`given award for teaching on the UK campus. Since its inception in 1961, 277 faculty members have
`been honored with this prestigious award
`
`Co-Editor of Special Issue in the Journal of Biomedical Nanotechnology. Volume 3, Number 2 (June
`2007)
`2006 AAPS Lipid-based Drug Delivery Award sponsored by Gattefossé Corporation
`Co-organizer and US Coordinator of the “Indo-US Symposium on Nanotechnology in Advanced Drug
`Delivery” held at the National Institute of Pharmaceutical Education and Research (NIPER), October
`5-6, 2006 in Punjab, India. Co-PI on proposal to secure funding from the Indo-US Science and
`Technology Forum (IUSSTF)
`Advisory Scientific Panel and Session Moderator on “Particulate Delivery Systems.” International
`Conference on Modern Vaccines: Adjuvants & Delivery Systems. The Royal Society of Medicine,
`London, United Kingdom. September 12-14, 2006
`Invited Panel Member on “Due Diligence.” The Power of Angel Investing. Kauffman Foundation.
`Lexington, Kentucky. October 31, 2005
`Robert A. Blouin Excellence in Pharmaceutical Graduate Education Award for Academic Year 2004-
`2005. Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky
`Best Paper Award 2003 in European Journal of Pharmaceutics and Biopharmaceutics.
`Award co-sponsored by APV and Elsevier and presented at the “International Meeting on
`Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology 2004” in Nuremberg, Germany.
`March 15-18, 2004. Paper by Z Cui and RJ Mumper titled “The Effect of Co-administration of
`Adjuvants with a Nanoparticle-based Genetic Vaccine Delivery System on the Resulting Immune
`Responses” published in Eur. J. Pharm. Biopharm. (2003) 55:11-18
`VivaGelTM, a topical dendrimer-based microbicidal gel developed by the CPST for Starpharma, was
`named one of the Top 5 Nanotech Breakthroughs of 2004 in the Forbes/Wolfe Nanotech Report
`(December 2004)
`Advisory Scientific Panel. International Conference on Modern Vaccines: Adjuvants & Delivery
`Systems. Dublin, Ireland. June 4-6, 2003
`Panel Moderator, Drug Discovery and Delivery. Life Sciences Without Boundaries. Ohio Valley
`Affiliates for Life Sciences (OVALS). Cincinnati, Ohio. March 10-11, 2003
`PhRMA Foundation Fellowship to Support Undergraduate Research in Pharmaceutics
`New Investigator Award, American Association of Colleges of Pharmacy
`Procter & Gamble AAPS Graduate Symposium in Drug Delivery and Pharmaceutical Technology
`Oswald Research and Creativity Award for Undergraduate Research, University of Kentucky
`Willard Riggs Meredith Award for Outstanding Undergraduate Chemistry Student, University of
`Kentucky
`Department of Energy Undergraduate Fellowship in Nuclear Chemistry and Radiochemistry
`1988
`University of Kentucky Honors Program Anniversary Scholarship
`1986
`1985–1987 University of Kentucky Alumni Association Scholarship
`1985–1987 President, University of Kentucky Student Alumni Council
`
`2006
`
`2005
`
`2005
`
`2004
`
`
`2004
`
`2003
`
`2003
`
`2001
`1999
`1991
`1988
`1988
`
`
`
`
`
`
`7
`
`
`
`DRL - EXHIBIT 1047
`DRL007
`
`

`
` Russell J. Mumper, Ph.D.
`
`CORPORATE, SCIENTIFIC ADVISORY BOARDS AND PATENT CONSULTING:
`
`
`enGene, Inc., Vancouver, British Columbia, Canada; Member, Scientific Advisory Board (2009-2016)
`Rothwell, Figg, Ernst, & Manbeck P.C., Washington, DC (2014-2015)
`Crowell & Moring LLP, New York, NY (2014-2015)
`Goodmans LLP, Toronto, Ontario, Canada (2013-2015)
`Alston & Bird LLP, New York, NY (2011- 2013)
`Corinthian Ophthalmic, Inc., Raleigh, North Carolina (2011-2012)
`Frommer Lawrence & Haug LLP, New York, NY (2008-2010)
`Isis Pharmaceuticals, Inc., Carlsbad, California (2008-2011)
`Sterne, Kessler, Goldstein & Fox P.L.L.C, Washington, DC (2008-2010)
`NanoMed Pharmaceuticals, Inc., Kalamazoo, MI (2000-2009)
`Affinium Pharmaceuticals, Austin, Texas and Toronto, Ontario (2007-2008)
`Federal Trade Commission, Washington, DC (2008)
`Merck & Co. Inc., West Point, Pennsylvania (2007)
`enGene, Inc., Vancouver, British Columbia, Canada (2006-2007)
`Sterne, Kessler, Goldstein & Fox P.L.L.C, Washington, DC (2005)
`Altea Therapeutics Corporation, Tucker, Georgia (2004)
`Dynogen Pharmaceuticals, Inc., Research Triangle Park (2004)
`BioDelivery Sciences International, Newark, New Jersey (2002- 2004)
`Dr. Reddy's Laboratories, Inc., Upper Saddle River, New Jersey (2003-2004)
`GlaxoSmithKline Consumer Healthcare, Parsippany, New Jersey (2003-2004)
`McKinsey & Company, New York, New York (2003-2004)
`Sterne, Kessler, Goldstein & Fox P.L.L.C, Washington, DC (2002)
`Niadyne, Inc., Tucson, Arizona (2000-2002)
`Access Pharmaceuticals, Dallas, Texas (1999-2001)
`Tigen Pharmaceuticals, Inc., Lexington, Kentucky (2001)
`Viridae Clinical Sciences, Inc., Vancouver, British Columbia (2000-2001)
`Intranasal Technologies Inc., Lexington, Kentucky (1999-2001)
`Caprion Pharmaceuticals, Montreal, Quebec, Canada (1999-2000)
`Atrix Laboratories, Fort Collins, Colorado (1998-1999)
`
`
`
`SACSCOC REVIEW PANELS:
`
`SACSCOC Offsite Reaffirmation Review Committee of 2016 Track B Institutions, Cluster 10. Atlanta,
`Georgia, November 5-6, 2015.
`
`
`
`SCIENTIFIC REVIEW PANELS:
`
`Echo360 Active Learning Grants Program. Echo360 Inc. July, 2013.
`Clinical Trials. National Institute on Deafness and Other Communication Disorders. ZDC1 SRB-L (48).
`NIDCD-National Institutes of Health. Teleconference. February 23, 2010.
`Chair. Multifunctional Particles for Targeting and Delivery Special Emphasis Panel ZGM1 CBB-4 (MP).
`ARRA Grand Opportunity. NIGMS-National Institutes of Health. Teleconference. August 12,
`2009.
`Drug Discovery ARRA. Special Emphasis Panel (ZRG1 OTC-B-96). Center for Scientific Review. National
`Institutes of Health. Teleconference. June 30, 2009.
`Vaccines for Immunotherapy of HIV. Special Emphasis Panel (ZAI1-EC-A M3). Program Application
`(P01). NIAID-National Institutes of Health. Teleconference. March 31, 2009.
`Division of Microbiology and Infectious Diseases (DMID), NIAID, NIH, BARDA – Application of Platform
`Technologies for the Development of Therapeutics for Biodefense. Gaithersburg, Maryland.
`October 16-17, 2008.
`AAPS Lipid-Based Drug Systems Focus Group – Review of AAPS Lipid-Based Drug Delivery Outstanding
`Research Award and AAPS Lipid-Based Drug Delivery Graduate Student Award. June, 2008.
`KAUST Research Fellows Competition. King Abdullah University of Science and Technology Global
`Research Partnership (GRP). April 4, 2008.
`2007 Breast Cancer Research Program (BCRP) Concept – Clinical and Experimental Therapeutics
`
`8
`
`
`
`
`
`
`
`
`
`
`
`
`DRL - EXHIBIT 1047
`DRL008
`
`

`
` Russell J. Mumper, Ph.D.
`
`(CET#5). Department of Defense, United States Army Medical Research and Materiel Command,
`Congressionally Directed Medical Research Programs (CDMRP). March 12, 2008.
`Vanderbilt University’s Intramural Discovery Grant Program (IDGP). Vanderbilt University. December
`19, 2007.
`Nanotechnology and Nanoscience Special Emphasis Panel (ZRG1 BCMB-S-50). Center for Scientific
`Review. National Institutes of Health. Bethesda, Maryland. February 22-23, 2007.
`HIV/AIDS Vaccine Study Section (VACC-3). Center for Scientific Review. National Institutes of Health.
`Bethesda, Maryland. July 13-14, 2006.
`Respiratory Integrative Biology and Translational Research (RIBT) Study Section. Special Emphasis Panel
`Bioengineering Research Applications – Respiratory. ZRG1 RES-D (52) (R). National Institutes
`of Health. June 14, 2006.
`Nanotechnology and Nanoscience Special Emphasis Panel (ZRG1 BCMB-A-50). Center for Scientific
`Review. National Institutes of Health. Bethesda, Maryland. July 11-12, 2005.
`Biophysical and Chemical Sciences Integrated Review Group (ZRG1 BPC-B-02). Center for Scientific
`Review, Special Emphasis Panel. National Institutes of Health. July 16, 2004.
`Biomedical Research Program. Florida Department of Health. June 9, 2004
`2003 Breast Cancer Research Program - Clinical Concept and Experimental Therapeutics. Department of
`Defense, United States Army Medical Research and Materiel Command, Congressionally Directed
`Medical Research Programs (CDMRP). March 12, 2004.
`Breast Cancer Research Program. Clinical and Experimental Therapeutics #3. Department of Defense,
`United States Army Medical Research and Materiel Command, Congressionally Directed Medical
`Research Programs (CDMRP). Reston, Virginia. July 30 – August 1, 2003.
`Brain Disorders and Clinical Neurosciences (SSS-S). Center for Scientific Review. SBIR/STTR Grant
`Applications. National Institutes of Health. Bethesda, Maryland. July 7-8, 2003.
`Seed Money for Cancer Research. Ohio Cancer Research Associates. March 24, 2003.
`NIH Predoctoral Fellowship Awards for Students with Disabilities (SSS-C). Center for Scientific Review.
`National Institutes of Health. Bethesda, Maryland. March 12, 2003.
`Medical Imaging Technologies Study Section (SSS-7). Center for Scientific Review. SBIR/STTR Grant
`Applications. National Institutes of Health. Bethesda, Maryland. March 3-4, 2003.
`Medical Imaging Technologies Study Section (SSS-7). Center for Scientific Review. National Institutes of
`Health. Teleconference. December 16, 2002.
`Drug Delivery and Drug Discovery Study Section (SSS-L). Center for Scientific Review, Special Emphasis
`Panel, Biophysical and Chemical Sciences. SBIR/STTR Grant Applications. National Institutes of
`Health, Silver Spring, Maryland. October 28-29, 2002.
`Microbicide Preclinical Development Program. Program Project Grants. National Institute of Child
`Health and Human Development & National Institute of Allergy and Infectious Diseases, National
`Institutes of Health. April 10, 2002.
`Biophysics and Chemistry. Center for Scientific Review, Special Emphasis Panel.